A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors

被引：2

作者：

Scotti, Vieri ^{[1
]}

Perna, Marco ^{[1
]}

Meacci, Fiammetta ^{[1
]}

Maragna, Virginia ^{[1
]}

Garlatti, Pietro ^{[1
]}

Vicini, Giulio ^{[2
]}

Pieretti, Giulia ^{[2
]}

Agresti, Benedetta ^{[1
]}

Mazzini, Cinzia ^{[2
]}

Livi, Lorenzo ^{[1
]}

机构：

[1] Univ Florence, Azienda Osped Univ Careggi, Radiat Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy

[2] Univ Florence, Azienda Osped Univ Careggi, Dept Surg & Translat Med, Unit Ocular Oncol, Florence, Italy

来源：

ANTI-CANCER DRUGS | 2020年 / 31卷 / 01期

关键词：

ALK rearrangement; choroidal metastasis; lung cancer; visus recovery; CRIZOTINIB; ALECTINIB;

D O I：

10.1097/CAD.0000000000000848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Choroidal localization from non-small cell lung cancer is rare and when it occurs may cause visual alterations. Targeted therapy against actionable gene mutations represents the standard of care in advanced non-small cell lung cancer. We report the case of a 53-year-old woman affected by metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ALK tyrosine kinase inhibitors, from January 2017. The patient had a complete response of choroidal metastasis after therapy with ALK tyrosine kinase inhibitors. She recovered a complete visus and actually she still continue therapy with alectinib. The patient had a complete recovery of visus in addiction to a long response on treatment. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：90 / 94

页数：5

共 50 条

[1] Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
Hu, Han
Dai, Hui
Ding, Liren
[J]. TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2967 - 2972
[2] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
Thompson, Jonathan R.
Menon, Smitha P.
Dy, Grace K.
[J]. ADMET AND DMPK, 2016, 4 (03): : 186 - 211
[3] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
Imase, R.
Endo, S.
Sasahara, Y.
Shinmura, T.
Ozawa, T.
Majima, H.
Hara, T.
Shimada, H.
Yamauchi, S.
Sakakibara, Y.
Kobayashi, A.
Yamazaki, K.
Jin, Y.
Yamanaka, K.
Matsubara, O.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
[4] Tyrosine kinase inhibitors in the management of non-small cell lung cancer
Perol, M.
Arpin, D.
[J]. REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S188 - S197
[5] STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
Feng, Chunlai
Zhou, Rong
Liu, Feng
Wang, Tingting
Liu, Sisi
Shao, Yang
[J]. FRONTIERS IN ONCOLOGY, 2021, 11
[6] Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases
Thomas, Christan M.
Lee, Chung-Shien
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 623 - 637
[7] Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
Jia, Caiyan
Xu, Qian
Zhao, Lu
Kong, Fanming
Jia, Yingjie
[J]. TRANSLATIONAL ONCOLOGY, 2024, 39
[8] Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
Vavala, Tiziana
Mariniello, Annapaola
Novello, Silvia
[J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S48 - S54
[9] Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
Sgambato, Assunta
Casaluce, Francesca
Maione, Paolo
Gridelli, Cesare
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) : 71 - 80
[10] Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
Riley, D.
Kaur, N.
Baglione, A.
Hall, R.
Barnes, L.
Gentzler, R.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1092 - S1092

← 1 2 3 4 5 →